Background: The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immune contexture of amplification in UC remain unclear.
Methods: This study analyzed 240 patients with UC with matched clinical annotations from two local cohorts (ZSHS cohort and FUSCC cohort). We assessed the correlation between status and clinical outcomes, therapeutic efficacy, and immunological characteristics by immunohistochemical analysis and targeted sequencing. Additionally, 2264 UC samples from five independent external cohorts, with genomic, transcriptomic, and clinical data, were used for validation.
Results: amplification ( ) or protein overexpression (MDM2) was associated with inferior overall survival (ZSHS cohort, Log-rank p<0.001; FUSCC cohort, Log-rank p=0.030) and reduced response to platinum-based chemotherapy (ZSHS cohort, Log-rank p<0.001) as well as anti-PD-1/PD-L1 immunotherapy (FUSCC cohort, Log-rank p=0.016) in patients with UC, irrespective of /p53 status. amplification or overexpression was further linked to high-grade UC tumors with dedifferentiated morphology. In addition, UC with amplification or overexpression was associated with an immuno-evasive contexture characterized by lower proportion of tertiary lymphoid structure infiltration, lower abundance of CD8 T cells, IFN-γ cells, GZMB cells, and decreased expression of immune checkpoint molecules including programmed death-ligand 1 (PD-L1), programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
Conclusions: amplification or overexpression defines a lethal subset of patients with UC with inferior prognosis and resistance to both platinum-based chemotherapy and immunotherapy irrespective of /p53 status. These tumors are characterized by dedifferentiated morphology and an immunosuppressive microenvironment. Accurate assessment of status can improve risk stratification and enable personalized genomics-guided treatment for patients with UC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jitc-2024-010964 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
Explor Target Antitumor Ther
November 2024
Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new classes of drugs that demonstrated pivotal improvements in terms of oncological responses and, ultimately, survival.
View Article and Find Full Text PDFThe optimization of dosing strategies is critical for maximizing efficacy and minimizing toxicity in drug development, particularly for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study demonstrates the utility of Nectin-4-targeted positron emission tomography (PET) imaging using [ Ga]AJ647 as a non-invasive tool for real-time assessment of target engagement in enfortumab vedotin (EV) therapy for urothelial carcinoma (UC). By leveraging the specificity of [ Ga]AJ647 for Nectin-4, we quantified dynamic changes in target engagement across preclinical models and established its correlation with therapeutic outcomes.
View Article and Find Full Text PDFPrognostic significance of systemic immune inflammation index in patients with urothelial carcinoma: a systematic review and meta-analysis.
Front Oncol
December 2024
Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, Sichuan, China.
Objective: This review assessed the prognostic significance of the systemic immune inflammation index (SII) in patients with urothelial carcinoma.
Methods: We performed a systematic review and cumulative meta-analysis of the primary outcomes according to the PRISMA criteria, and assessed study quality. Seven databases were searched: Embase, PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed, from the creation of each database until October 2024.
We studied the effect of urinary urea concentration on the hemolysin production and cytotoxicity of the uropathogenic Morganella morganii strain MM 190. The highest hemolytic activity of M. morganii cultivated in urine with low urea concentration (23 and 82 mmol/liter) was observed between 3rd and 4th hours of post-inoculation, while in urine with standard urea level (117 mmol/liter), the activity was observed at 5th hour of post-inoculation.
View Article and Find Full Text PDF[Detection and interpretation of PD-L1 in urologic neoplasms].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing100191, China.
Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors. Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy. The current application status of PD-L1 detection for urinary system tumors (mainly urothelial carcinoma), methods of the different antibody tests and the precautions, challenges and solutions in the interpretation of immunostaining were summarized in this review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!